Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.


BACKGROUND Vasoreactivity testing is recommended in the management of pulmonary arterial hypertension (PAH), but its clinical relevance in congenital heart disease (CHD)-associated PAH has not been established. OBJECTIVE To determine whether residual pulmonary vascular responsiveness to intravenous. epoprostenol is predictive of clinical outcome in… (More)
DOI: 10.1136/hrt.2010.199661

6 Figures and Tables


  • Presentations referencing similar topics